CD4 and acute myeloid leukemia: To mend this gap, our group performed a proof-of-concept single-cell polyfunctional study on a subset of patients with RelRef AML treated with azacitidine combined with nivolumab (Aza/Nivo) and identified that the polyfunctional activity of CD4 T cells predicted responses to therapy (19).